Nanocarry Therapeutics
Nanoparticle-based Therapeutics for Brain Cancer and CNS Disorders
Company Overview
Snapshot
Founded in January 2021 by Revital Mandil Levin, Rachela Popovtzer, and Oshra Betzer, Nanocarry Therapeutics operates with 11–50 employees. The company has raised $1 million across 4 funding rounds from 3 investors.
Business overview
Nanocarry Therapeutics is a Health Tech & Life Sciences company focused on developing nanoparticle-based therapeutics for oncology indications and brain diseases. The company's core technology is the AxS platform, which utilizes bioengineered nanoparticles to deliver biologics safely and effectively to the brain and other areas. Nanocarry Therapeutics is currently developing its first products for brain metastases of HER2+ breast cancer and non-small cell lung cancer, operating within the Digital Healthcare, Digital Therapeutics, Pharma & Medical Biotechnology, and Drugs Discovery & Development sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is Nanocarry Therapeutics' primary focus?
- Nanocarry Therapeutics is developing therapeutics based on bioengineered nanoparticles designed to treat oncology indications and brain diseases, with an initial focus on brain metastases of HER2+ breast cancer and non-small cell lung cancer.
- When was Nanocarry Therapeutics founded and by whom?
- Nanocarry Therapeutics was founded in January 2021 by Revital Mandil Levin, Rachela Popovtzer, and Oshra Betzer.
- What is the AxS platform?
- The AxS platform is Nanocarry Therapeutics' proprietary technology, utilizing bioengineered nanoparticles that can be modified to deliver a wide array of biologics safely and effectively to the brain and beyond.